Illumina, Inc. (ILMN)
ILMN moved a median of +0.02% 30 minutes after news, and +0.17% by the close. How ILMN actually reacts to news — the realized, point-in-time move the market made, measured across 914 labeled events over the last three years with zero look-ahead.
ILMN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.06% | 46% | 911 |
| 30-min | +0.02% | 51% | 911 |
| 60-min | +0.05% | 53% | 911 |
| to close | +0.17% | 53% | 906 |
| Middle 50% of ILMN reactions | -0.62% to +0.72% |
|---|---|
| Median reaction (30-min) | +0.02% |
| Measured reactions | 914 |
Half of all Illumina, Inc. news events land between -0.62% and +0.72% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ILMN reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 44 | -0.59% | 41% | -0.22% |
| Analyst downgrades | 42 | +0.41% | 64% | +1.12% |
| Coverage initiations | 26 | +1.41% | 89% | +1.30% |
| Rating reiterations | 150 | +0.08% | 52% | +0.90% |
| Price-target raises | 37 | +0.27% | 65% | +1.58% |
| Price-target cuts | 35 | +0.21% | 66% | +0.30% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how ILMN ranks against every other measured name →
That’s how ILMN usually reacts — get an email when it moves on news →Email me when ILMN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ILMN's baseline. Nothing else.
Recent ILMN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs | Press release | PR Newswire | +1.05% | +0.95% | |
| Form 8-K ILLUMINA, INC. For: Oct 13 | SEC filing · Form 8-K | SEC EDGAR | +1.05% | +0.95% | |
| Illumina releases SpliceAI2 to help advance rare disease research | Press release | PR Newswire | -0.94% | +0.33% | |
| Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026 | Press release | PR Newswire | -0.30% | +3.71% | |
| Form 8-K ILLUMINA, INC. For: Aug 17 | SEC filing · Form 8-K | SEC EDGAR | -0.11% | -1.69% | |
| Form 8-K ILLUMINA, INC. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +0.53% | +0.44% | |
| Form 8-K ILLUMINA, INC. For: Aug 10 | SEC filing · Form 8-K | SEC EDGAR | -0.23% | +0.47% | |
| Form 8-K ILLUMINA, INC. For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | +2.33% | — | |
| Form 10-Q ILLUMINA, INC. For: Jun 28 | SEC filing · Form 10-Q | SEC EDGAR | -2.22% | -2.93% | |
| Form 8-K ILLUMINA, INC. For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | -2.27% | +0.90% | |
| Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026 | Press release | PR Newswire | -2.27% | +0.90% | |
| Illumina expands Billion Cell Atlas program with new AI drug developers | Press release | PR Newswire | -0.01% | +1.15% | |
| Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer | Press release | PR Newswire | +0.49% | +2.80% | |
| Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026 | Press release | PR Newswire | -0.64% | -1.59% | |
| Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors | Press release | PR Newswire | +0.73% | +2.70% | |
| Form 8-K ILLUMINA, INC. For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | +0.73% | +2.70% | |
| Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution | Press release | PR Newswire | -2.00% | -2.68% | |
| Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights | Press release | Business Wire | +1.02% | +2.21% | |
| Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research | Press release | PR Newswire | -0.21% | +1.40% | |
| Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research | Press release | PR Newswire | +1.33% | +5.73% | |
| Form 8-K ILLUMINA, INC. For: May 21 | SEC filing · Form 8-K | SEC EDGAR | +0.07% | +3.75% | |
| David P. King elected to Illumina's Board of Directors | Press release | PR Newswire | -0.03% | -0.19% | |
| Form SD ILLUMINA, INC. | SEC filing · Form SD | SEC EDGAR | -2.07% | +0.11% | |
| Illumina releases 2025 Corporate Responsibility Report, expanding access to genomics and accelerating global impact | Press release | PR Newswire | -2.07% | +0.11% | |
| Form 10-Q ILLUMINA, INC. For: Mar 29 | SEC filing · Form 10-Q | SEC EDGAR | +0.59% | +2.89% | |
| Form 8-K ILLUMINA, INC. For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | -3.42% | +1.92% | |
| Illumina Reports Financial Results for First Quarter of Fiscal Year 2026 | Press release | PR Newswire | -3.42% | +1.92% | |
| DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows | Press release | PR Newswire | -1.05% | +0.68% | |
| Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease | Press release | PR Newswire | +1.51% | +2.78% | |
| Form ARS ILLUMINA, INC. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.35% | -3.31% | |
| Form DEF 14A ILLUMINA, INC. For: May 21 | SEC filing · Form DEF | SEC EDGAR | -1.35% | -3.31% | |
| Form DEFA14A ILLUMINA, INC. | SEC filing · Form DEFA14A | SEC EDGAR | -1.35% | -3.31% | |
| Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026 | Press release | PR Newswire | -1.35% | -3.31% | |
| Form 8-K ILLUMINA, INC. For: Apr 02 | SEC filing · Form 8-K | SEC EDGAR | +0.15% | +2.36% | |
| Illumina Announces Changes to Board of Directors | Press release | PR Newswire | +0.15% | +2.36% | |
| Illumina and Labcorp expand collaboration to broaden access to precision oncology testing | Press release | PR Newswire | +1.10% | +2.16% | |
| Illumina advances preventive genomics through strategic consortium with Veritas Genetics | Press release | PR Newswire | +1.02% | -0.60% | |
| Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering | Press release | PR Newswire | +0.14% | +0.45% | |
| Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida | Press release | PR Newswire | +5.16% | +5.80% | |
| Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected Multiomics | Press release | PR Newswire | +5.16% | +5.80% | |
| Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics | Press release | PR Newswire | -0.51% | +3.78% | |
| Illumina launches TruPath Genome, setting a new standard in genomic insight | Press release | PR Newswire | +0.25% | -0.25% | |
| Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics | Press release | PR Newswire | -1.09% | -1.58% | |
| Illumina launches TruPath Genome, setting a new standard in genomic insight | Press release | PR Newswire | +0.11% | +0.16% | |
| Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility | Press release | PR Newswire | +1.39% | +1.68% | |
| Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility | Press release | PR Newswire | -0.01% | +3.42% | |
| Illumina To Webcast Upcoming Investor Conference | Press release | PR Newswire | -0.21% | -0.08% | |
| Form 10-K ILLUMINA, INC. For: Dec 28 | SEC filing · Form 10-K | SEC EDGAR | -0.90% | -1.94% | |
| Form 8-K ILLUMINA, INC. For: Feb 05 | SEC filing · Form 8-K | SEC EDGAR | +0.40% | -4.98% | |
| Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025 | Press release | PR Newswire | +0.40% | -4.98% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ILMN section they belong to.
Where else ILMN is measured.
ILMN earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Perrigo Company plc Ordinary Shares (PRGO) | 916 | +0.04% | 50% |
| PORTOLA PHARMACEUTICALS (PTLA) | 915 | -0.04% | 48% |
| Twist Bioscience Corporation (TWST) | 914 | -0.01% | 50% |
| Boston Scientific Corporation (BSX) | 912 | +0.07% | 54% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Illumina, Inc.'s median reaction calculated?
Every labeled ILMN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 914 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of ILMN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ILMN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.